Literature DB >> 326963

Strain variation in BCG-induced chronic pulmonary inflammation in mice. I. Basic model and possible genetic control by non-H-2 genes.

E M Allen, V L Moore, J O Stevens.   

Abstract

C57BL/6 mice (haplotype H-2b) responded in a dose-dependent fashion to killed BCG by marked enlargement of the spleen and lung. Neither CBA nor C3H mice (haplotype H-2k) responded to such treatment. Pulmonary inflammation in responder B6 animals was characterized by a marked chronic interstitial and alveolar granulomatous process, and was accompanied by occasional granulomata, hyperemia, and loss of architecture in the spleen. Inflammation in non-responder CBA and C3H animals was minimal in both the lung and spleen. The response does not appear to be controlled by genes within the major histocompatibility complex, but is associated with a C57 background. B10.BR mice (responder background, H-2k) were responder animals and C3H.SW mice (nonresponder background, H-2b) were nonresponders. In addition, all animals tested with a C57 background were responders even though two of these strains were not H-2b (C57BL/Ks, H-2d and C57Br/cd, H-2k). The resolution of the mechanism of genetic control of this response in mice may provide information relevant to possible genetic control of chronic pulmonary inflammation in man.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 326963

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  26 in total

1.  Genetic control of streptococcus-induced hepatic granulomatous lesions in mice.

Authors:  C Y Chen; S A Cohen; M B Zaleski; B Albini
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

2.  Strain difference of delayed-type hypersensitivity to BCG and its genetic control in mice.

Authors:  R M Nakamura; T Tokunaga
Journal:  Infect Immun       Date:  1978-12       Impact factor: 3.441

3.  Mechanisms in the in vivo release of lymphokines: relationship of high and low responsiveness to other parameters of the immune response.

Authors:  R Neta; S B Salvin
Journal:  Infect Immun       Date:  1981-10       Impact factor: 3.441

4.  Immunoregulation in hypersensitivity pneumonitis. I. Differences in T-cell and macrophage suppressor activity in symptomatic and asymptomatic pigeon breeders.

Authors:  R H Keller; J N Fink; S Lyman; G Pedersen
Journal:  J Clin Immunol       Date:  1982-01       Impact factor: 8.317

5.  Strain differences in lung granuloma formation in response to a BCG cell-wall vaccine in mice. Failure of antigen presentation by low-responder macrophages.

Authors:  M Kakinuma; K Onoé; R Yasumizu; K Yamamoto
Journal:  Immunology       Date:  1983-11       Impact factor: 7.397

6.  Host response to infection with a temperature-sensitive mutant of Salmonella typhimurium in a susceptible and a resistant strain of mice.

Authors:  C Nauciel; F Vilde; E Ronco
Journal:  Infect Immun       Date:  1985-09       Impact factor: 3.441

7.  Role of macrophages in innate and acquired host resistance to experimental scrub typhus infection of inbred mice.

Authors:  T R Jerrells; J V Osterman
Journal:  Infect Immun       Date:  1982-09       Impact factor: 3.441

8.  Failure of C3H mice to develop lung granuloma after intravenous injection of BCG cell wall vaccine. Demonstration of a defect in lymphoid cells.

Authors:  M Kakinuma; K Onoé; M Okada; T Kimura; K Kato; H Okuyama; K Morikawa; K Yamamoto
Journal:  Immunology       Date:  1981-05       Impact factor: 7.397

9.  Pathological observations of lung inflammation after administration of IP-10 in influenza virus- and respiratory syncytial virus-infected mice.

Authors:  Hong Luo; Dong Wang; Hai-Long Che; Yue Zhao; Hong Jin
Journal:  Exp Ther Med       Date:  2011-09-09       Impact factor: 2.447

10.  Depressed in vitro and in vivo antibody response and adoptive transfer of delayed hypersensitivity to myoglobin with spleen cells of mice chronically infected with Schistosoma japonicum and injected with myoglobin.

Authors:  K S Garb; A B Stavitsky
Journal:  Infect Immun       Date:  1984-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.